LQDA - Liquidia Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.47
-0.54 (-5.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.01
Open8.99
Bid0.00 x 800
Ask0.00 x 800
Day's Range8.01 - 9.02
52 Week Range8.01 - 38.46
Volume325,542
Avg. Volume122,335
Market Cap157.816M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.00
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed safety and exploratory endpoint findings at the two-month timepoint for the Phase 3 INSPIRE trial. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, presented the data at the opening plenary session of the 39th International Society for Heart & Lung Transplantation (ISHLT) Meeting and Scientific Sessions in Orlando, Florida. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using its PRINT® Technology, as an alternative to current inhaled treprostinil therapy for the treatment of patients with pulmonary arterial hypertension (PAH) (WHO Group 1).

  • GlobeNewswire21 days ago

    Liquidia Technologies to Present at Needham Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., April 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire29 days ago

    Liquidia Technologies Announces Closing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswirelast month

    Liquidia Technologies Announces Pricing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 21, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Morrisville company looks to Wall Street — again
    American City Business Journalslast month

    Morrisville company looks to Wall Street — again

    Less than a year after its IPO, this Morrisville company wants to raise more cash to fund its core competencies.

  • GlobeNewswirelast month

    Liquidia Technologies Announces Proposed Offering of Common Stock

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswirelast month

    Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line results of its pivotal Phase 3 INSPIRE study in patients with pulmonary arterial hypertension (“PAH”) treated with LIQ861, the first inhaled dry powder formulation of treprostinil. Initial analysis indicates the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, stated: “The top-line analysis of LIQ861 from the INSPIRE study is highly encouraging for physicians and patients.

  • GlobeNewswire2 months ago

    Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trialAccepted by FDA into Emerging Technology Program to support review of PRINT®.

  • GlobeNewswire2 months ago

    Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019

    RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire3 months ago

    Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today reported positive interim safety data from its open-label, multicenter Phase 3 clinical trial (INSPIRE) evaluating LIQ861, an inhaled dry powder formulation of treprostinil, for the treatment of pulmonary arterial hypertension (“PAH”). Patients adding LIQ861 to current non-prostacyclin oral therapies started at a dose of approximately 25 mcg and those transitioned from nebulizer-delivered treprostinil at a stable dose were initiated at a dose of LIQ861 lower than their current stable treprostinil dose.

  • GlobeNewswire5 months ago

    Liquidia Technologies Provides Leadership Update

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that Kevin Gordon, President and Chief Financial Officer, plans to retire from his current role at Liquidia to focus on board and other advisory work. Liquidia has initiated a search process for a new CFO and Mr. Gordon has agreed to continue his employment with the company until March 1, 2019 to support a smooth transition. “On behalf of Liquidia’s employees and Board of Directors, I want to thank Kevin for his many contributions and wish him the best in his next chapter,” stated Neal Fowler, Chief Executive Officer of Liquidia.

  • Liquidia Technologies Inc (NASDAQ:LQDA): Time For A Financial Health Check
    Simply Wall St.5 months ago

    Liquidia Technologies Inc (NASDAQ:LQDA): Time For A Financial Health Check

    Liquidia Technologies Inc (NASDAQ:LQDA) is a small-cap stock with a market capitalization of US$309m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • GlobeNewswire5 months ago

    Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire5 months ago

    Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within Harvest Capital Credit, Zynga, Unique Fabricating, SJW Group, Liquidia Technologies, and Rave Restaurant Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Liquidia Technologies to Present at Jefferies London Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Liquidia Technologies refocuses efforts
    American City Business Journals6 months ago

    Liquidia Technologies refocuses efforts

    Following its initial public offering this summer, Liquidia Technologies is buckling down in preparation for its new drug application next year.

  • GlobeNewswire6 months ago

    Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen.

  • Benzinga8 months ago

    Liquidia Well-Positioned With PRINT, Jefferies Says

    Liquidia Technologies Inc. (NASDAQ: LQDA ) has developed a PRINT technology, which serves as a particle engineering platform to enable production of uniform drug particles. This platform allows the company ...

  • Business Wire9 months ago

    Liquidia Technologies Announces Closing of Initial Public Offering

    Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the closing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share for gross proceeds of $50.0 million before underwriting discounts and commissions. In addition, the Company has granted the underwriters a 30-day option to purchase up to 681,818 additional shares of common stock at the initial public offering price, less the underwriting discount.

  • Business Wire9 months ago

    Liquidia Technologies Announces Pricing of Initial Public Offering

    Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the pricing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions, for gross proceeds of $50.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to 681,818 additional shares of common stock at the initial public offering price, less the underwriting discount.